摘要
Abstract
Objective:To analyze the effect of niraparib-adjuvant chemotherapy on short-term efficacy and survival in patients with advanced ovarian cancer(OC).Methods:A total of 100 patients with advanced OC admitted to a hospital from January 2021 to January 2024 were retrospectively selected.According to the treatment regimen,patients were divided into the control group(n=53,treated with first-line chemotherapy alone)and the study group(n=47,treated with first-line chemotherapy combined with niraparib).Both groups received 6 courses of treatment.Short-term efficacy,serum tumor marker[carcino-embryonic antigen(EA),carbohydrate antigen 19-9(CA19-9),human epididymis protein 4(HE4)],immune function,incidence of adverse reactions,and 1-year follow-up overall survival rate were compared between the two groups.Results:The objective response rate in the study group(31.92%)was higher than that in the control group(7.55%,P<0.05).After 6 courses of treatment,CEA,CA19-9,HE4,CD3+and CD4+decreased in both groups.The levels of CEA,CA19-9,and HE4 in the study group were lower than those in the control group,while the levels of CD3+and CD4+were higher than those in the control group(P<0.05).The incidences of alopecia,leukopenia,and proteinuria in the study group were lower than those in the control group,while the incidence of thrombocytopenia was higher(P>0.05).After 1 year of follow-up,the overall survival rate in the study group was higher than that in the control group(P<0.05).Conclusion:Niraparib-adjuvant therapy for patients with advanced OC is beneficial for inhibiting serum tumor marker levels,alleviating immune impairment,and prolonging survival.关键词
尼拉帕利/晚期卵巢癌/疗效/生存期/肿瘤标志物Key words
niraparib/advanced ovarian cancer/efficacy/survival time/tumor markers分类
医药卫生
